Anti-Human CCR7 Reference Antibody (CAP-100, RUO) (HB053026)

价格:

规格：

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量：

一键复制产品信息

概述
图片
参考文献
产品说明书

货号	HB053026
品牌	abinScience
种属反应性	Human
应用	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
同种型	IgG
克隆号	CAP-100
生物活性	CAP-100 (0.1-10 ng/uL) demonstrates the most potent binding to CCR7 immunogen SYM1899 (100 ng) with a EC 50 of 1.78 ng/mL [1]. CAP-100 (0.01-100 ug/mL) shows dose-dependent inhibition of ligand-induced activation, reaching maximal inhibitions close to 100% in CCR7 + CHO-K1 cells stimulated with CCL19 [1]. CAP-100 (0.1-100 ug/mL) binds to CCR7 + non-tumor PB or BM cells from healthy donors at high experimental concentrations [1]. CAP-100 (1-100 ug/mL) impairs the increase of D-actin upon CCL19/CCL21 stimulation in CLL cells [1]. CAP-100 (0.1-100 ug/mL, 4 h) demonstrates a strong dose-related inhibitory activity against CCR7-driven T-PLL cells migration towards 1 ug/mL of CCL19 or CCL21 [1]. CAP-100 (10 ug/mL) impairs CCR7-induced migration of CCL cells in trans-endothelial migration (TEM) assays [1]. CAP-100 (10-100 ug/mL, 24 h) does not mediate direct specific-induced cell death but impairs the viability of CCR7-mediated cells which is the protective function in CLL [1]. CAP-100 (10 ug/mL) activated human NK-92-CD16 + cells to induce a strong ADCC on target CLL cells [1]. CAP-100 (10 ug/mL, i.v., one single dose) reduces in vivo homing of CCR7-expressing cells to lymph node of NSG mice [1]. CAP-100 (25-200 ug/mouse, i.v., one single dose) shows prolonged median overall survival regardless of dose and reduces tumor burden as well as reducing lymph node infiltration in Granta-519-luc + -bearing mice [1]. CAP-100 (10-200 ug/mouse, i.v., one single dose) significantly extends the lifespan of JVM-3-bearing SCID mice compared to Trastuzumab () (200 ug) [1].
表达系统	Mammalian cells
靶标	CDw197, EVI1, CMKBR7, CCR7, C-C CKR-7, CD197, CCR-7, Epstein-Barr virus-induced G-protein coupled receptor 1, MIP-3 beta receptor, EBI1, CC-CKR-7, BLR2, EBV-induced G-protein coupled receptor 1, C-C chemokine receptor type 7
内毒素水平	< 10 EU/mg
纯度	>95% purity as determined by SDS-PAGE.
纯化方式	Protein A/G purified from cell culture supernatant.
Accession号	P32248
状态	Liquid
保存溶液	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
稳定性和存储	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名	CAP-100, CAP100, CAP100
背景	C-C chemokine receptor type 7 (CD197/CCR7) is a ~42 kDa protein. Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions.
文献	1. Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13(1):1917484. [HB053026]
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107)

Bioactivity

SEC-HPLC detection for Research Grade Anti-Human CD197/CCR7 (CAP-100).
SDS-PAGE

SDS-PAGE for Research Grade Anti-Human CD197/CCR7 (CAP-100).

产品说明书

Anti-Human CCR7 Reference Antibody (CAP-100, RUO).pdf

质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)

填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。

分子量 *

g/mol

C₁ × V₁ = C₂ × V₂

填写 4 项中的任意 3 项，自动计算未知值。

C₁ (起始浓度)

V₁ (起始体积)

C₂ (终浓度)

V₂ (终体积)

重组蛋白

抗体

试剂盒

实验相关试剂

Anti-Human CCR7 Reference Antibody (CAP-100, RUO) (HB053026)

概述

图片

参考文献

产品说明书

相关产品推荐

重组蛋白

抗体

试剂盒

实验相关试剂

Anti-Human CCR7 Reference Antibody (CAP-100, RUO) (HB053026)

概述

图片

参考文献

产品说明书

相关产品推荐

获取报价